Comment on the article of E.A. Lebedeva et al. “Basic therapy of traumatic brain injury using catecholamine agonist”
ISSN (print) 1726-9806     ISSN (online) 1818-474X
#2018-1
PDF_2018-1_83 (Russian)

How to Cite

Belkin A.A. Comment on the article of E.A. Lebedeva et al. “Basic therapy of traumatic brain injury using catecholamine agonist”. Annals of Critical Care. 2018;(1):83. .

Statistics

Annotation views: 251
PDF_2018-1_83 (Russian) downloads: 77

Language

Social Networks

Keywords

Abstract

Comment on the article of E.A. Lebedeva et al. “Basic therapy of traumatic brain injury using catecholamine agonist”
PDF_2018-1_83 (Russian)

References

  1. Samson A.J., Robertson G., Zagnoni M., Connolly C.N. Neuronal networks provide rapid neuroprotection against spreading toxicity. Sci. Rep. 2016; 6: 33746. doi: 10.1038/srep33746.
  2. Giacino J.T., Whyte J., Bagiella E., et al. Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. N. Engl. J. Med. 2012; 366(9): 819–826. doi: 10.1056/NEJMoa1102609.
  3. Kalmar K., Childs N., et al. Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. Rehabilitation. 2012; 366(9): 819–826. doi: 10.1056/NEJMoa110260.
  4. Belkin A.A., Shchegolev A.V., Kondrat’ev A.N., Bubnova I.D. Use of amantadine sulfate (PK-MERZ) during emergence from coma: results of a multicenter study. Anesteziol. Reanimatol. 2008; 2: 70–73. PMID: 18540467.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2018 ANNALS OF CRITICAL CARE